Internal Medicine · Anaheim, CA
NPI
1063421865
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
515 S Beach Blvd, Ste F
Anaheim, CA, 92804
Phone (714) 995-7503
Groups this clinician bills Medicare through
Medicare paid, 2024
$655K
8,850 services
Medicare patients, 2024
898
Average age 75
Drug cost, 2024
$2.0M
22,172 prescriptions
Company payments, 2025
$9,347
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fariborz Shams was code 99232 (hospital e&m - subsequent), 2,495 times for 234 patients. In total Fariborz Shams billed 8,850 services in 39 codes, and Medicare paid $655K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,495 | 234 | $61.98 | $155K |
| 99308 SNF E&M | Facility | 2,451 | 380 | $59.27 | $145K |
| 99233 Hospital E&M - Subsequent | Facility | 808 | 278 | $93.27 | $75K |
| 99214 Office E&M - Established | Office | 529 | 149 | $93.19 | $49K |
| 99306 SNF E&M | Facility | 486 | 341 | $144.05 | $70K |
| 99495 Chronic, Principal, and Transitional Care Management | Facility | 391 | 293 | $110.72 | $43K |
| 99223 Hospital E&M - Initial | Facility | 310 | 263 | $136.06 | $42K |
| 99308 SNF E&M | Office | 268 | 47 | $46.39 | $12K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 225 | 89 | $51.16 | $12K |
| 99238 Hospital Discharge Management | Facility | 176 | 158 | $64.56 | $11K |
| 99213 Office E&M - Established | Office | 139 | 82 | $65.44 | $9,097 |
| 99211 Office E&M - Established | Office | 73 | 43 | $18.19 | $1,328 |
| G0008 Administration of influenza virus vaccine | Office | 40 | 40 | $35.02 | $1,401 |
| 36415 Venipuncture Blood Collection | Office | 38 | 23 | $8.65 | $329 |
| G0179 Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 31 | 19 | $35.29 | $1,094 |
By year: 2022 $583K for 7,772 services; 2023 $483K for 6,324 services; 2024 $655K for 8,850 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 38 | 23 | $8.65 | $329 |
Medicare prescription drug claims, 2024
In 2024, the drug Fariborz Shams prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,107 prescriptions and refills. In total Fariborz Shams wrote 22,172 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,107 | 1,537 | 200 | $9,746 |
| Levothyroxine Sodium Generic | 806 | 1,020 | 125 | $8,414 |
| Amlodipine Besylate Generic | 669 | 964 | 136 | $3,727 |
| Metoprolol Tartrate Generic | 638 | 756 | 97 | $4,660 |
| Gabapentin Generic | 602 | 707 | 92 | $12K |
| Losartan Potassium Generic | 482 | 777 | 101 | $4,100 |
| Metformin Hcl Generic | 458 | 649 | 82 | $3,433 |
| Eliquis Apixaban | 448 | 466 | 59 | $149K |
| Pantoprazole Sodium Generic | 414 | 514 | 76 | $21K |
| Famotidine Generic | 362 | 463 | 77 | $3,564 |
| Levetiracetam Generic | 351 | 379 | 45 | $10K |
| Memantine Hcl Generic | 346 | 350 | 49 | $9,777 |
| Tamsulosin Hcl Generic | 328 | 428 | 68 | $3,992 |
| Omeprazole Generic | 324 | 387 | 75 | $2,574 |
| Ipratropium-Albuterol Ipratropium/Albuterol Sulfate | 298 | 298 | 63 | $6,960 |
Brand drugs: 3,612 claims; generic drugs: 18,461 claims; opioid claims: 121.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fariborz Shams $9,347 ($9,347 in general payments such as food, travel and fees) from 17 companies. The largest payer was Neurocrine BioSciences, Inc. with $6,264.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 10 | $6,264 |
| Becton, Dickinson and Company BDX | 2 | $2,250 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 2 | $156 |
| Janssen Biotech, Inc. JNJ | 1 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 3 | $76.71 |
| ACADIA Pharmaceuticals Inc ACAD | 2 | $66.4 |
| Lundbeck LLC | 3 | $57.01 |
| Alkermes, Inc. ALKS | 2 | $45.09 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $43.25 |
| Lilly USA, LLC LLY | 2 | $39.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.